Clinical trial
Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in…
NCT00004104 · NYU Langone Health, Other · Completed
Key facts
| NCT number | NCT00004104 |
|---|---|
| Title | Vaccine Therapy Plus Interleukin-2 With or Without Interferon Alfa-2b in Treating Patients With Stage III Melanoma |
| Official title | Phase II Trial of the Effects of Interferon Alfa-2b on the Immunogenicity of a Polyvalent Melanoma Antigen Vaccine in Patients With Stage III Malignant Melanoma |
| Lead sponsor | NYU Langone Health, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | liposomal interleukin-2, polyvalent melanoma vaccine, recombinant interferon alfa |
| Start date | Jun 1, 1998 |
| Primary completion | Jul 1, 2000 |
| First posted | Jul 19, 2004 |
| Last update posted | Mar 31, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: